Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol

Toxicology

Volumn 144, Issue 1-3, 2000, Pages 221-228

  Aigner, Achim ^a   Hsieh, Susie S ^b   Malerczyk, Claudius ^a   Czubayko, Frank ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Oncogene; Ovarian cancer; Taxol

Indexed keywords

CISPLATIN; DOXORUBICIN; PACLITAXEL; RIBOZYME;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; NORTHERN BLOTTING; ONCOGENE NEU; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL LINE; CISPLATIN; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; PLASMIDS; RECEPTOR, ERBB-2; RNA, CATALYTIC;

EID: 0034599545     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-483X(99)00210-3     Document Type: Article

References (26)

1. Alimandi M., Romano A., Curia M.C. et al. Cooperative signaling of erbB3 and erbB2 in neoplastic transformation and human malignancies. Oncogene. 10:1995;1813-1821.
2. Alroy I., Yarden Y. The erbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Letts. 410:1997;83-86.
3. Baselga J., Norton L., Albanell J., Kim Y.M., Mendelsohn J. Recombinant humanized anti-HER2 antibody (herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu over-expressing human breast cancer xenografts. Cancer Res. 58(13):1998;2825-2831.
4. Czubayko F., Downing S.G., Hsieh S.S. et al. Adenovirus-mediated transduction of ribozymes abrogates HER-2/neu and pleiotrophin expression and inhibits tumor cell proliferation. Gene Ther. 4:1997;943-949.
5. Czubayko F., Riegel A.T., Wellstein A. Ribozyme-targeting elucidates a direct role of pleiotrophin in tumor growth. J. Biol. Chem. 269:1994;21358-21363.
6. Fang W., Hartmann N., Chow D.T., Riegel A.T., Wellstein A. Pleiotrophin stimulates fibroblasts and endothelial and epithelial cells and is expressed in human cancer. J. Biol. Chem. 267:1992;25889-25897.
7. Goldenberg M.M. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin. Ther. 21(2):1999;309-318.
8. Graus-Porta D., Beerli R.R., Daly J.M., Hynes N.E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 16:1997;1647-1655.
9. Hurwitz E., Stancovski I., Sela M., Yarden Y. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. Proc. Natl. Acad. Sci. USA. 92:1995;3353-3357.
10. Juhl H., Downing S.G., Wellstein A., Czubayko F. HER-2/neu is rate-limiting for ovarian cancer growth: conditional depletion of HER-2/neu by ribozyme targeting. J. Biol. Chem. 272:1997;29482-29486.
11. Karunagaran D., Tzahar E., Beerli R.R. et al. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J. 15:1996;254-264.
12. Muss H.B., Thor A.D., Berry D.A. et al. c-erbB-2 Expression and respose to adjuvant therapy in woman with node-positive early breast cancer. New Engl. J. Med. 330:1994;1260-1266.
13. Pegram M.D., Lipton A., Hayes D.F. et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu over-expressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16(8):1998;2659-2671.
14. Peles E., Yarden Y. Neu and its ligands: from an oncogene to neural factors. Bioessays. 15:1993;815-824.
15. Pinkas-Kramarski R., Alroy I., Yarden Y. ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signaling. J. Mamm. Gland Biol. Neoplasia. 2:1997;97-107.
16. Plowman G.D., Culouscou J.M., Whitney G.S. et al. Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc. Natl. Acad. Sci. USA. 90:1993;1746-1750.
17. Plowman G.D., Green J.M., Culouscou J.M. et al. Heregulin induces tyrosine phosphorylation of HER4/p180erbB4. Nature. 366:1993;473-475.
18. Salomon D.S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19:1995;183-232.
19. Shak S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2 over-expressing metastatic breast cancer: herceptin multinational investigator study group. Semin. Oncol. 26(4 Suppl. 12):1999;71-77.
20. Slamon D.J., Clark G.M., Wong S.G. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science. 235:1987;177-182.
21. Slamon D.J., Godolphin W., Jones L.A. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:1989;707-712.
22. Stancovski I., Sela M., Yarden Y. Regulatory Mechanisms of Breast Cancer. 1994;161 Kulwer, Boston.
23. Tsai C.M., Chang K.T., Perng R.P. et al. Correlation of intrinsic chemoresistance of non small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J. Natl. Cancer Inst. 85:1993;897-901.
24. Tsai C.M., Yu D., Chang K.T. et al. Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells. J. Natl. Cancer Inst. 87:1995;682-684.
25. Tzahar E., Waterman H., Chen X. et al. hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol. Cell Biol. 16:1996;5276-5287.
26. Yu D., Jing T., Sun D. et al. Over-expression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene. 16(16):1998;2087-2094.